APA (7th ed.) Citation

L, D., N, M., E, N., J, T., S, M., L, G., . . . P, I. (2026). Elevated C-Reactive Protein as a Potential Biomarker for Neurological Adverse Events in Immune Checkpoint Inhibitor Therapy: A Prospective Cohort Study. Oncology research, 34(5), 17. https://doi.org/10.32604/or.2026.074095

Chicago Style (17th ed.) Citation

L, Duzzi, et al. "Elevated C-Reactive Protein as a Potential Biomarker for Neurological Adverse Events in Immune Checkpoint Inhibitor Therapy: A Prospective Cohort Study." Oncology Research 34, no. 5 (2026): 17. https://doi.org/10.32604/or.2026.074095.

MLA (9th ed.) Citation

L, Duzzi, et al. "Elevated C-Reactive Protein as a Potential Biomarker for Neurological Adverse Events in Immune Checkpoint Inhibitor Therapy: A Prospective Cohort Study." Oncology Research, vol. 34, no. 5, 2026, p. 17, https://doi.org/10.32604/or.2026.074095.